Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03987061
Other study ID # FCRE-190131
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 5, 2019
Est. completion date July 1, 2024

Study information

Verified date March 2023
Source FCRE (Foundation for Cardiovascular Research and Education)
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this clinical evaluation is to evaluate the immediate and long-term (up to 36 months) outcome of the MOTIV™ Bioresorbable Scaffold (Reva Medical) in a controlled prospective investigation for the treatment of patients with rest pain or minor tissue loss (CLI) due to the presence of lesions of max 100mm in length at the level of the below-the-knee arteries.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 58
Est. completion date July 1, 2024
Est. primary completion date July 1, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient is willing to comply with specified follow-up evaluations at the specified times - Patient presenting with rest pain or minor tissue loss (Rutherford classification from 4 to 5) - Patient is >18 years old - Patient understands the nature of the procedure and provides written informed consent, prior to enrollment in the study - Patient has a projected life-expectancy of at least 24-months - Patient is eligible for treatment with the MOTIV™ Bioresorbable Scaffold - Male, infertile female, or female of child bearing potential practicing an acceptable method of birth control with a negative pregnancy test within 7 days prior to study procedure - De novo lesion or Restenotic lesion after PTA in the infrapopliteal arteries, suitable for endovascular therapy - Target vessel diameter visually estimated to be =2.5mm and =3.50mm - Guidewire and delivery system successfully traversed the lesion - Total target lesion is maximally 100mm - Definition of Target Lesion is: 1. short de novo or Restenotic lesion after PTA or 2. a short residual flow-limiting dissection or restenosis after PTA of a longer lesion Exclusion Criteria: - The reference segment diameter is not suitable for the available stent design - Untreated flow-limiting aortoiliac stenotic disease - Perioperative unsuccessful ipsilateral percutaneous vascular procedure to treat inflow disease just prior to enrollment. - Any previous surgery in the target vessel - Aneurysm located at the target vessel - Non-atherosclerothic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis) - Severe medical comorbidities (untreated CAD/CHF, severe COPD, metastatic malignancy, dementia, etc) or other medical condition that would preclude compliance with the study protocol or 2-year life expectancy. - Major distal amputation (above the transmetatarsal) in the study or non-study limb. - Septicemia or bacteremia - Any previously known coagulation disorder, including hypercoagulability - Contraindication to anticoagulation or antiplatelet therapy - Known allergies to scaffold or scaffold components - Known allergies to contrast media that cannot be adequately premedicated prior to the study procedure - Patient with known hypersensitivity to heparin-induced thrombocytopenia (HIT) type II - Currently participating in another clinical research trial

Study Design


Intervention

Device:
MOTIV BVS
MOTIVS BVS in below-the-knee artery disease

Locations

Country Name City State
Austria Hospital Floridsdorf Vienna
Germany Klinikum Hochsauerland Arnsberg
Germany Bad Oeyhausen Klinik für Allgemeine und Interventionelle Kardiologie/Angiologie Bad Oeynhausen
Germany Medizinische Versorgungszentren GmbH Berlin
Germany University Hospital Leipzig, Angiology Leipzig
Germany Katholisches Klinikum Mainz; Akademisches Lehrkrankenhaus der Johannes Gutenberg-Universität Mainz Mainz
Germany St. Franziskus-Hospital Münster
Germany University Hospital Münster, Angiology Münster

Sponsors (1)

Lead Sponsor Collaborator
Dr. Sabrina Overhagen

Countries where clinical trial is conducted

Austria,  Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary efficacy endpoint - Primary Patency rate at 12-months post-op Primary patency defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio =2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months. 12 months post-op
Primary safety endpoint - rate of serious device-related adverse events within 30 days post-op Proportion of subjects who experience serious device-related adverse events within 30 days post-procedure. 30 days post-op
Secondary Technical Success Technical Success, defined as the ability to cross and dilate the lesion to achieve residual angiographic stenosis no greater than 30% 1-day post-op
Secondary Primary Patency rate at follow-up visits Primary patency rate defined as no evidence of at least 50% restenosis or reocclusion within the originally treated lesion based on color-flow-duplex ultrasound (CFDU) measuring a peak systolic velocity ratio =2.5, and/or angiography (left at the discretion of the investigator) without target lesion revascularization (TLR) within 12 months. 1 month, 6 months, 12 months, 24 months and 36 months post-op
Secondary Clinically-driven target lesion revascularization (TLR) at 1, 6, 12, 24 and 36-months Clinically-driven (drop in 1 Rutherford Classification) target lesion revascularization (TLR) is defined as a repeat intervention to maintain or re-establish patency within the region of the treated arterial vessel plus 5mm proximal and distal to the device/PTA edge 1 month, 6 months, 12 months, 24 months and 36 months post-op
Secondary Limb-Salvage rate at follow-up visits Major amputation is defined as amputation at or above the ankle, as opposed to minor amputation, being an amputation at or below metatarsal level, preserving functionality of the foot. 1 month, 6 months, 12 months, 24 months and 36 months post-op
Secondary Clinical success at follow-up visits Clinical success at follow-up is defined as an improvement of Rutherford classification at 1 day and 1-, 6-, 12-, 24- and 36-months follow-up of one class or more as compared to the pre-procedural Rutherford Classification. 1 day post-op and 1 month, 6 months, 12 months, 24 months and 36 months post-op
Secondary Serious adverse events during the study (within 36 months post-op) Serious adverse events as defined as any clinical event that is fatal, life-threatening, or judged to be severe by the investigator; resulted in persistent or significant disability; necessitated surgical or percutaneous intervention; or required prolonged hospitalization. within 36 months post-op
See also
  Status Clinical Trial Phase
Recruiting NCT06032065 - Sequential Multiple Assessment Randomized Trial of Exercise for PAD: SMART Exercise for PAD (SMART PAD) Phase 3
Recruiting NCT03506633 - Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients N/A
Active, not recruiting NCT03506646 - Dietary Nitrate Supplementation and Thermoregulation N/A
Active, not recruiting NCT04677725 - NEtwork to Control ATherothrombosis (NEAT Registry)
Recruiting NCT05961943 - RESPONSE-2-PAD to Reduce Sedentary Time in Peripheral Arterial Disease Patients N/A
Recruiting NCT06047002 - Personalised Antiplatelet Therapy for Patients With Symptomatic Peripheral Arterial Disease
Completed NCT03185052 - Feasibility of Outpatient Care After Manual Compression in Patients Treated for Peripheral Arterial Disease by Endovascular Technique With 5F Sheath Femoral Approach N/A
Recruiting NCT05992896 - A Study of Loco-Regional Liposomal Bupivacaine Injection Phase 4
Completed NCT04635501 - AbsorbaSeal (ABS 5.6.7) Vascular Closure Device Trial N/A
Recruiting NCT04584632 - The Efemoral Vascular Scaffold System (EVSS) for the Treatment of Patients With Symptomatic Peripheral Vascular Disease From Stenosis or Occlusion of the Femoropopliteal Artery N/A
Withdrawn NCT03994185 - The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive Disease N/A
Withdrawn NCT03538392 - Serranator® Alto Post Market Clinical Follow Up (PMCF) Study
Recruiting NCT02915796 - Autologous CD133(+) Cells as an Adjuvant to Below the Knee Percutaneous Transluminal Angioplasty Phase 1
Active, not recruiting NCT02900924 - Observational Study to Evaluate the BioMimics 3D Stent System: MIMICS-3D
Completed NCT02901847 - To Evaluate the Introduction of a Public Health Approach to Peripheral Arterial Disease (PAD) Using National Centre for Sport and Exercise Medicine Facilities. N/A
Not yet recruiting NCT02387450 - Reduced Cardiovascular Morbi-mortality by Sildenafil in Patients With Arterial Claudication Phase 2/Phase 3
Not yet recruiting NCT02455726 - Magnesium Oral Supplementation to Reduce Pain Inpatients With Severe Peripheral Arterial Occlusive Disease N/A
Withdrawn NCT02126540 - Trial of Pantheris System, an Atherectomy Device That Provides Imaging While Removing Plaque in Lower Extremity Arteries N/A
Completed NCT02022423 - Physical Activity Daily - An Internet-Based Walking Program for Patients With Peripheral Arterial Disease N/A
Completed NCT02384980 - Saving Life and Limb: FES for the Elderly With PAD Phase 1